Weight-loss drugs may fight 7 serious health problems before the pounds even come off
Research suggests GLP-1 medicines used for weight loss may also affect several other health conditions, including heart and kidney disease, joint pain and inflammation. Some benefits have been seen in clinical trials, but researchers are still working out how much is due to effects beyond weight loss.
The article describes seven potential benefits, with evidence of varying strength. In trials, semaglutide reduced major kidney complications and cardiovascular death by 24% in people with type 2 diabetes and chronic kidney disease, while 62.9% of participants with MASH saw the condition resolve without worsening liver scarring, compared with 34.3% on placebo. Other research links these medicines to fewer respiratory flare-ups, possible mental health and addiction benefits, and improved psoriasis; some findings are preliminary or observational.
- GLP-1 medicines may offer benefits beyond weight loss.
- Trials reported heart, kidney, liver and joint benefits.
- Evidence for some other effects remains preliminary.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
GLP-1 medicines may offer meaningful health benefits beyond weight loss, with trials reporting fewer major kidney complications and cardiovascular deaths in some people with diabetes and chronic kidney disease, and improved MASH outcomes compared with placebo. If further research confirms benefits for other conditions, these medicines could address several health risks at once and improve patients’ quality of life.
The case against
The evidence is uneven: some findings come from preliminary or observational research, and it remains unclear how much improvement reflects effects of the medicines themselves rather than weight loss. Claims about benefits across many conditions could therefore get ahead of the evidence; larger, longer studies are needed to establish which patients benefit and how reliably.